Articles

BIO is committed to increased access to biologic medicines for patients throughout the world. 

The Patent Reform Act of 2011 would strengthen and improve our nation’s patent system, spurring innovation and job creation.

Thank you for submitting your BIO Board and Section-Level Committee Designation form. The relevant BIO committee representative (s) will contact you soon to confirm your committee assignments.

Position Title: Managing Director, Business Solutions

Department: Public Affairs / Member Services

Reports to: Vice President, External Affairs & Member Services                  

Position summary: 

Thank you for registering for the 2014 CSBA/SGRC Retreat! If you have any question please contact Caitlin Van Sant at cvansant@bio.org.

All BIO members benefit from access to networking opportunities, members’ only committees, as well as discounts at conferences and on business services and supplies from major brands. In addition to the standard member benefits, BIO is pleased to offer unique and recently expanded benefits to its law firms members.

BIO Business Solutions

Position Title: Manager, Partnering Operations

Department: Business Development

Reports to: Director, Partnering Products & Services

Position summary: 

Chair: Adam Monroe, President,  Novozymes North America, Novozymes 
Staff Contact: Brent Erickson, Executive Vice President, Industrial & Environmental, berickson@bio.org.  

Co-Chair: Timothy Cooke, Chief Executive Officer, Novadigm Therapeutics, Inc.
Co-Chair: Angela Hwang, U.S. Regional Lead, Pfizer, Inc.
Staff Contact: Phyllis Arthur, Senior Director, Vaccines, Immunotherapetuics and Diagnostics Policy, parthur@bio.org.

Co-Chair: Richard Pops, Chairman & CEO, Alkermes, plc
Co-Chair: John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals, Inc.
Staff Contact: Andrew Emmett, Managing Director for Science and Regulatory Affairs, aemmett@bio.org.  

Co-Chair: Alex Azar, President, Eli Lilly, USA
Co-Chair: Kristine Peterson, Chief Executive Officer, Valeritas, Inc.
Staff Contact: Laurel Todd, Managing Director for Reimbursement and Health Policy, ltodd@bio.org.    

Chair: Scott Kohne, Market Acceptance Manager, NAFTA, Bayer CropScience, Inc.
Vice Chair: Jeffrey Nawn, Senior Manager, Biotech Affairs and Regulatory, Dupont Pioneer
Staff Contact: Adrianne Massey, Managing Director, Science & Regulatory Affairs, amassey@bio.org.

Chair: Ronald Stotish, Chief Executive Officer, Aqua Bounty Technologies, Inc.        
Vice Chair: Robin Readnour, Senior Director, Technology Acquisition & Biological Product Development, Elano, Inc.
Staff Contact: Cathleen Enright, Executive Vice President, Food & Agriculture, cenright@bio.org.   

Co-Chair: Steven Mento, Co-Founder, President, CEO, & Chairman, Conatus Pharmaceuticals, Inc.
Co-Chair: Hal Van Wart, President & CEO, CymaBay Therapeutics
Staff Contact:  Cartier Esham, Executive Vice President, Emerging Companies, cesham@bio.org.   

Co-Chair: Douglas Doerfler, Chief Executive Officer, MaxCyte, Inc.
Co-Chair: John Orwin, Chief Executive Officer, Relypsa, Inc.
Staff Contact: Shelly Mui-Lipnik, Senior Director, Capital Formation & Financial Services Policy, smui-lipnik@bio.org

Description: Review and develop policy on legislative and regulatory tax issues (including net operating loss and R&D credits, securities law issues (Sarbanes-Oxley, short selling), accounting (revenue recognition, IFRS), federal grant programs (SBIR, TIP), and other capital formation initiatives.

Members:
Christopher Nolet, Partner, Ernst & Young, LLP

Faheem Hasnain, President & CEO, Receptos, Inc.

Gil Van Bokkelen, Chairman & CEO, Athersys Inc.
Hans Schikan, Chief Executive Officer, Prosensa, Inc.

Jeffrey Hatfield, President & CEO, Vitae Pharmaceuticals, Inc.

John Mendlein, President, CEO & Chairman, aTyr Pharma, Inc.

Jonathan Leff, Partner & Chairman, Deerfield Management Company, LP

Kleanthis Xanthopoulos, President & CEO, Regulus Therapeutics, Inc.

Martin Babler, President & CEO, Principia Biopharma, Inc.

Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.

Perry Karsen, Chief Executive Officer, Celgene Cellular Therapeutics, Inc.

Robert Kiss, Managing Director & Portfolio Manager, JPMorgan Asset Management

Stuart Peltz, President & CEO, PTC Therapeutics, Inc.

Timothy Walbert, Chairman, President & CEO, Horizon Pharma, Inc.

 Co-Chair:  Douglas Doerfler, Chief Executive Officer, MaxCyte, Inc.

Co-Chair:  John Orwin, Chief Executive Officer, Relypsa, Inc.
Staff Contact:  Shelly Mui-Lipnik, Senior Director, Capital Formation & Financial Services Policy, smui-lipnik@bio.org

Description:   Review and develop policy on legislative and regulatory tax issues (including net operating loss and R&D credits, securities law issues (Sarbanes-Oxley, short selling), accounting (revenue recognition, IFRS), federal grant programs (SBIR, TIP), and other capital formation initiatives.

Members:
Christopher Nolet, Partner, Ernst & Young, LLP

Faheem Hasnain, President & CEO, Receptos, Inc.

Gil Van Bokkelen, Chairman & CEO, Athersys Inc.
Hans Schikan, Chief Executive Officer, Prosensa, Inc.

Jeffrey Hatfield, President & CEO, Vitae Pharmaceuticals, Inc.

John Mendlein, President, CEO & Chairman, aTyr Pharma, Inc.

Jonathan Leff, Partner & Chairman, Deerfield Management Company, LP

Kleanthis Xanthopoulos, President & CEO, Regulus Therapeutics, Inc.

Martin Babler, President & CEO, Principia Biopharma, Inc.

Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.

Perry Karsen, Chief Executive Officer, Celgene Cellular Therapeutics, Inc.

Robert Kiss, Managing Director & Portfolio Manager, JPMorgan Asset Management

Stuart Peltz, President & CEO, PTC Therapeutics, Inc.

Timothy Walbert, Chairman, President & CEO, Horizon Pharma, Inc.

 


 

 


 

 

Chair: Vacant
Staff Contact: Kenneth Lisaius, Senior Vice President, Communications, klisaius@bio.org

Description: The committee oversees BIO’s communications, media relations, website, public education, focus groups, and external outreach initiatives.

Chair: Paul Hastings, President & CEO, OncoMed Pharmaceuticals, Inc.
Staff Contact: Frederick Bittenbender, Executive Vice President, Public Affairs, fbittenbender@bio.org

Description:  The committee oversees BIO’s Alliance Development initiatives and strategic engagement with third party stakeholders including patient advocacy, provider, and other organizations committed to ensuring the development of and access to innovative therapies. 

Chair: Peter Greenleaf, Chief Executive Officer, Sucampo Pharmaceuticals, Inc. 
Staff Contacts: Frederick Bittenbender, Executive Vice President, Public Affairs, fbittenbender@bio.org

Chair: David Pyott, Chairman & CEO, Allergan, Inc. 
Staff Contact: Joseph Damond, Senior Vice President, International Affairs, jdamond@bio.org  

Description:The committee oversees, in conjunction with other relevant BIO committees, BIO’s international work plan objectives to foster an environment conducive to biotechnology, re-shape the debate on IP and pro-innovation policies, and influence regulatory reform and harmonization discussions in key international markets.  The committee’s jurisdiction includes oversight of BIO’s International Affairs Initiative, international organization matters (e.g., WHO, WTO, WIPO, APEC, OECD), international advocacy and education programs, international studies, and coordinating efforts of foreign peer organizations.

Chair: VACANT 
Staff Contact: Tom DiLenge, General Counsel & Head of Public Policy, tdilenge@bio.org

Description: The committee oversees domestic intellectual property (IP) issues (e.g., patent system reforms, Patent and Trademark Office administrative & policy matters, judicial developments, and IP budgetary issues), and international IP issues (e.g., TRIPS, WTO, WHO, CBD), and other trade-related agreements).

Chair: Perry Karsen, Chief Executive Officer, Celgene Cellular Therapeutics, Inc.
Staff Contact: Amy Finan, Senior Vice President, Business Operations, afinan@bio.org

Chair: Alexis Borisy, Chairman, Forma Therapeutics, Inc.
Staff Contact: Sara Radcliffe, Executive Vice President, Health Section, sradcliffe@bio.org

Chair: Daniel Junius, President & CEO, ImmunoGen, Inc.
Vice Chair: Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, Inc. 
Staff Contact: Joanne Duncan, Senior Chief Financial Officer and Vice President, Finance & Administration, jduncan@bio.org.